Following overseas reports of serious and unpredictable hepatotoxicity associated with the use of the catechol- O-methyl transferase inhibitor, tolcapone (Tamar), including 3 fatalities, its registration has been withdrawn in Australia.

Reference: Australian Adverse Drug Reactions Bulletin Vol. 18, No. 1, February 1999.